Spots Global Cancer Trial Database for A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Official Title: Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Study ID: NCT03913741
Conditions
Interventions
Study Description
Brief Summary: Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
Detailed Description: Part 1 of this trial will determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and the safety profile of tisotumab vedotin in subjects with solid malignancies. Part 2 of this trial will enroll subjects with cervical cancer to provide further data on the safety, tolerability, PK and anti-tumor activity
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Cancer Center Hosptial East, Kashiwa-shi, Chiba-Ken, Japan
NHO Shikoku Cancer Center, Matsuyama-Shi, Ehime-Ken, Japan
NHO Hokkaido Cancer Center, Sapporo-shi, Hokkaido, Japan
Kanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan
Saitama Medical University International Medical Center, Hidaka-shi, Saitama-Ken, Japan
Shizuoka Cancer Center, Sunto-gun, Shizuoka-Ken, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan
Keio University Hospital, Shinjuku-ku, Tokyo-To, Japan
Contact Details
Name: Keiichi Fujiwara, Professor
Affiliation: Saitama Medical University International Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
